Is Cytokinetics Inc (CYTK) a risky stock?
As of July 28, 2026, Clavix grades Cytokinetics Inc (CYTK) A for risk, a composite score of 88 out of 100 on an A+ to F scale, which puts CYTK in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 28, 2026. Clavix regrades every trading day.
The five risk dimensions behind CYTK's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CYTK scores on each, as of July 28, 2026.
What's moving CYTK's risk right now
Company-specific signals Clavix flags behind CYTK's current grade, drawn from recent news and filings as of July 28, 2026.
Director Blum exercised options at $10.60 and sold at $82.02 after a 122% one-year gain, keeping 381,986 shares. Siren L.L.C. opened a $40.47 million stake, mixing insider profit-taking with fresh institutional interest.
Cytokinetics is now a commercial-stage biotech after FDA approval and EU authorization of Myqorzo for obstructive HCM. Positive topline results from the ACACIA-HCM trial in non-obstructive HCM will be presented at the ESC Congress 2026.
Following Myqorzo's FDA approval, Cytokinetics is seeing early US uptake and European expansion alongside lifecycle studies. The commercial push comes as the company faces competition in the HCM market.
Recent CYTK news
The latest headlines Clavix ingested for Cytokinetics Inc, newest first. These feed the news-sentiment dimension of CYTK's grade.
-
Siren L.L.C. disclosed a new $40.47 million position in Cytokinetics (CYTK) via its Q1 13F filing, acquiring 613,952 shares, which now represent 1.1% of the hedge fund's portfolio.
What a A grade means
On the Clavix A+ to F scale, CYTK's composite of 88 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CYTK or any security. Grades are risk indicators, not predictions of return. Data may be delayed.